Compare UCL & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCL | TELA |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.0M | 41.3M |
| IPO Year | 2019 | 2019 |
| Metric | UCL | TELA |
|---|---|---|
| Price | $1.03 | $0.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 13.5K | ★ 105.0K |
| Earning Date | 05-20-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $80,275,000.00 |
| Revenue This Year | $11.60 | $10.23 |
| Revenue Next Year | N/A | $14.26 |
| P/E Ratio | $13.72 | ★ N/A |
| Revenue Growth | N/A | ★ 15.84 |
| 52 Week Low | $0.95 | $0.50 |
| 52 Week High | $4.19 | $2.19 |
| Indicator | UCL | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 45.49 | 49.54 |
| Support Level | N/A | $0.79 |
| Resistance Level | $1.19 | $0.91 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 50.00 | 36.31 |
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data-related products globally. Its uCloudlink cloud SIM platform is designed for shared mobile data connectivity services by allocating the SIM cards remotely and dynamically to users. Ucloudlink's core business is to provide mobile data connectivity services at competitive prices, which it delivers through a range of hardware products and service solutions to its business partners, retail, and enterprise customers. The main hardware terminals offered by the company include portable Wi-Fi terminals, smartphones, and smart-hardware products for international and local mobile data connectivity services. Geographically, it generates maximum revenue from Japan.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.